CANCELLED Meeting Announcement – SUGAMMADEX

Posted by on June 7, 2013

July 18, 2013 8:00 a.m. to 5:00 p.m.:  Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement


Where:  FDA White Oak Campus
               Building 31
               The Great Room (Rm. 1503)
               White Oak Conference Center
               10903 New Hampshire Avenue
               Silver Spring, Maryland

Please click HERE for the current roster of the Anesthetic and Analgesic Drug Products Advisory Committee.The committee will discuss new drug application (NDA) 022225, sugammadex sodium injection, submitted by Organon USA Inc., for the proposed indications of routine reversal of moderate and deep neuromuscular blockade (NMB) induced by rocuronium or vecuronium and immediate reversal of NMB at three minutes after administration of rocuronium.


ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact